Privi Speciality Chemicals Ltd Q3 FY2025 Concall Summary

Key Takeaways

• Margin surprise despite revenue dip: Planned plant shutdowns pulled revenue below Q2, yet EBITDA margin rose above the normal sustainable level, driven by a favorable product mix and internal efficiency gains.
• Confident 20% growth pledge for FY26: Management reiterated its minimum 20% revenue growth target, anchored by a 65-70% order book for calendar 2025 and a 7-10% price increase taking effect from Q4.
• Capacity build-out is the core story: Incremental capex of INR250-300 crores over 15-18 months targets flagship products, while the Givaudan JV has commenced commercial production and co-manufacturing dialogues with competitors are underway.
• Air freight masked underlying margin strength: Other expenses spiked to ~16% of revenue per ton solely due to air freight from U.S. port strikes; excluding this, margins would have been stable, and the efficiency trend is called secular.
• What to watch next quarter: Whether the 7-10% price hike sticks in Q4 volumes, the pace of the Givaudan JV ramp-up, and any disclosure on competitor co-manufacturing deals as NDAs allow.

Margin Drivers & Cost Structure

• Product mix shift, not pricing: Most products sell under annual contracts, so the margin lift came from a richer mix of higher-margin products and internal efficiency steps: improved yields, lower power and steam consumption, and better plant utilization. Management called the trend secular.
• Continuous processes lowering cost: New continuous processes for some key products have been developed, directly reducing the cost of production.
• Green power adding savings: An increased share of green power contributed to cost savings while strengthening the company's ESG commitment.
• Air freight inflated other expenses: Other expenses rose significantly to ~16% or INR72,000 per ton because U.S. port strikes and sea voyage uncertainty forced customers to request airlifting of material. Management confirmed that eliminating this impact would have kept margins roughly flat.
• ESG scores improving: The CDP project score improved significantly, and the company holds a current gold rating from EcoVadis, with a stated goal to improve further.

Sanjeev Patil: "Largely, this is driven by 2 factors. First factor is the change in product mix. But don't let me give you out the name so that my competition as my customers wake up. But the change in product mix is one of the reasons why the profitability has improved and will remain improved."

Revenue Growth & Order Book

• 20% growth target reaffirmed: Management is "very bullish" on maintaining its minimum 20% revenue growth track record for FY25-26, with volume growth implied at roughly 15%.
• Order book provides visibility: Approximately 70% of business is contracted with large MNCs on a calendar-year basis, and 65-70% of calendar 2025 is already booked, giving confidence in the revenue target.
• Price increases landing Q4: Price increases ranging from 7-8% to close to 10% across products became applicable from Q4, with a marginal portion of Q4 sales already carrying the new prices.
• India and Africa as growth engines: Management sees upward of 20% growth from Indian and African markets, citing very low per capita consumption and huge growth headroom.
• North America decline was capacity rationing: The year-on-year decline in North America and rest-of-world business was not a loss of business but a deliberate rationing of capacity to service additional demand from other countries.
• Musk and specialty segment share rising: The traction in the musk and specialty revenue segment has stayed in a similar band over three quarters, but its share appears to be rising because each product is growing from a much lower base.

Mahesh Babani: "We are very bullish that we will surely be able to maintain our original track record of minimum 20% growth for the year 25-26. We are confident that we'll achieve this."

Capacity Expansion & Capex

• INR250-300 crore capex plan: The company will spend this amount over the coming 15 to 18 months on debottlenecking, capacity increases in flagship products, and immediate new products emerging from R&D.
• Prionyl capacity already live: Capacity for Prionyl has already been increased and became operational during February.
• Debottlenecking volume undisclosed: Management declined to quantify the incremental capacity from debottlenecking but called it "significant" and sufficient to cover volume growth for at least the next 1 to 2 years.
• Fixed asset turnover on capex: Around 1.5x, per management.
• Capex funded internally and via debt: Short-term capex requirements will be met through internal accruals and debt; the balance sheet is strong enough for additional borrowing, and a QIP may be planned at an opportune time.
• Capacity beyond FY26: Beyond debottlenecking and flagship expansion, new products from R&D are expected to support the growth path beyond FY26.

Sanjeev Patil: "And you should take the overall capacity number with a lot of thought and not a pinch of salt, a lot of thought because there are products which sell from \$3 to products which sell at \$15, \$75, \$100 also."

Strategic Initiatives & Partnerships

• Givaudan JV (PRIGIV) now commercial: Commercial production has commenced and the inauguration was held with a very senior Givaudan team traveling to Mumbai. The ramp-up is on track as planned.
• Prionyl and Amber Woody Xtreme on track: Capacities have been set up and volumes are progressing as planned; margins on these products were described only as "healthy."
• Co-manufacturing with competitors in play: The company has initiated dialogue with some competitors to work as co-producers and has signed an NDA. Management called the opportunities "extremely interesting" but declined to share details, citing a critical and sensitive stage.
• New R&D products are high-value: New products under development are described as unique, high-value, and high-margin, though management declined to name them to avoid awakening competition.
• Privi Fine Sciences integration deferred: The integration timeline remains undefined; management will inform stakeholders at the appropriate time and it currently operates separately.

Sanjeev Patil: "Listen, these are some extremely interesting opportunities. But please mind that we have already signed an NDA, we cannot be talking about this information about in public. In due course of time, you will, of course, get the good news, and it should always be disclosed to our dearest shareholders."

Camphor & Pharma Progress

• Camphor running at full capacity: Camphor will realize its advantage this year and more, and will continue to operate at full capacity through this financial year.
• Pharma entry is a long game: The company is shortlisting and supplying samples to pharma companies, completing regulatory compliances including drug master files, and pursuing FDA certification. Management cautioned that the U.S. FDA route is a very long-drawn process.
• Patience framed as a virtue: The longer the regulatory timeline, "the better will be the fruits," per management, implying high barriers to entry once approved.

Sanjeev Patil: "You have to realize that getting through the U.S. FDA route is a very long-drawn process. But the longer you wait, the better will be the fruits."

External Risks & Mitigants

• Geopolitics seen as manageable: Management does not expect the geopolitical situation to hamper growth too much as of now; growth is expected to stay in place.
• Trade tariffs not a differential threat: No change of tariff applies on raw material imports, and Unit 2 is an export-oriented unit where duties do not matter. Management does not foresee differential challenges against other countries, though it will face any situation as it comes.
• Working capital cycle target: The ideal working capital cycle should be around 125 to 135 days.
• New geographies already served: The company already sells in South Asia and China markets.

Guidance & Commitments

Key Metrics